Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329030 · ClinicalTrials.gov registry record · Phase 3
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 224
- Enrollment target
NCT00329030 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 224 participants.
The verdict
NCT00329030, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 224 participants
- Enrollment target
Study Summary
This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard Rituxan plus BEAM transplant regimen versus a regimen adding Bexxar to BEAM.
Interventions
- DRUG Autologous transplantation using rituxan/BEAM
- DRUG Autologous transplantation using Bexxar/BEAM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2005-12 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329030
The ClinicalTrials.gov registry entry for NCT00329030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Autologous transplantation using rituxan/BEAM is the first listed.
NCT00329030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329030 about?
NCT00329030 is a clinical study titled "Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)". This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard Rituxan plus BEAM transplant regimen versus a regimen adding Bexxar to BEAM.
What is the current status of trial NCT00329030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2005-12. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00329030?
The interventions under investigation include: Autologous transplantation using rituxan/BEAM (DRUG), Autologous transplantation using Bexxar/BEAM (DRUG).
Who is sponsoring clinical trial NCT00329030?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.